Cord Blood News Volume 4.29 | Jul 26 2012

Primary Hematopoietic Cells from Diamond-Blackfan Anemia Patients with Mutations in RPL11 and RPS19 Genes Exhibit Distinct Erythroid Phenotype In Vitro
Ribosomal protein (RP)S19 mutations induced a decrease in proliferation of progenitor cells, but the terminal erythroid differentiation was normal with little or no apoptosis. In marked contrast, RPL11 mutations led to a dramatic decrease in progenitor cell proliferation and a delayed erythroid differentiation with a marked increase in apoptosis and G₀/G₁ cell cycle arrest with activation of p53. Infection of cord blood CD34⁺ cells with specific short hairpin RNAs against RPS19 or RPL11 recapitulated the two distinct phenotypes in concordance with findings from primary cells. [Cell Death Dis] Full Article

Calcium Phosphate Cement with Biofunctional Agents and Stem Cell Seeding for Dental and Craniofacial Bone Repair
Researchers aimed to incorporate biofunctional agents into calcium phosphate cement (CPC), and to investigate human umbilical cord mesenchymal stem cell seeding on biofunctionalized CPC for osteogenic differentiation for the first time. [Dent Mater] Abstract

Development of a Mechanically Tunable 3D Scaffold for Vascular Reconstruction
Scientists described an approach to modulate the mechanical properties of an ex vivo derived scaffold by machining variable wall thicknesses to control compliance. Reseeded smooth muscle cells were shown to adhere, proliferate, and migrate from the scaffold surface showing the potential of the human umbilical artery as a mechanically “tunable” material with applications as an acellular implant or as a tissue engineered construct. [J Biomed Mater Res A] Abstract

A Study on Mutual Interaction Between Cytokine Induced Killer Cells and Umbilical Cord-Derived Mesenchymal Cells: Implication for Their In Vivo Use
Investigators provided experimental data on the mutual interaction of cytokine-induced-killer cells and umbilical cord-mesenchymal stromal cells, suggesting a negative interference when the two cell types are used in combination. [Blood Cells Mol Dis] Abstract

Acute Maternal Cytomegalovirus Infection Is Associated with Significantly Decreased Numbers of CD34+ Cells in Umbilical Cord Blood
Researchers found that umbilical cord blood donated by anti-cytomegalovirus IgM-positive women has a high probability of not meeting the criteria required for cryopreservation for future use as a transplantation product, because of the low number of CD34+ cells. [Blood Cells Mol Dis] Abstract

Enhancement of Bone Formation by Genetically Engineered Human Umbilical Cord-Derived Mesenchymal Stem Cells Expressing Osterix
The authors investigated if overexpression of osterix in human umbilical cord-derived mesenchymal stem cells would facilitate osteogenic differentiation in bone regeneration. [Oral Surg Oral Med Oral Pathol Oral Radiol] Abstract

Pluristem Partners with CPC Clinical Research for Peripheral Artery Disease Study
Pluristem Therapeutics, Inc. announced that in anticipation of initiating a Phase II study using PLX-peripheral artery disease cells for the treatment of Intermittent Claudication, the company has recently entered into a collaborative agreement with CPC Clinical Research for services related to enrolling and sustaining clinical sites. [Pluristem Therapeutics, Inc.] Press Release

Pluristem Therapeutics Set to Enter Bone Marrow Disease Market as It Is Preparing to Apply for Orphan Drug Status with the FDA for the Treatment of Aplastic Bone Marrow
Pluristem Therapeutics, Inc. announced it is preparing to apply to the U.S. Food and Drug Administration (FDA) for approval of its PLacental eXpanded cells for the treatment of aplastic bone marrow as an Orphan Drug. [Pluristem Therapeutics, Inc.] Press Release

Shire’s Advanced BioHealing Renamed Shire Regenerative Medicine
Shire plc announced that Advanced BioHealing, Inc., which was acquired by Shire in 2011 as a wholly-owned subsidiary focused on regenerative medicine, has changed its name to Shire Regenerative Medicine, Inc. [Shire plc] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications & Publishing Coordinator (STEMCELL Technologies, Inc.)

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Stem Cell Therapy Scientist (Paramount Recruitment)

BMS Specialist/BMS Advanced Specialist (NHS Blood and Transplant)

Clinical Lab Scientist – Cord Blood (Cardinal Glennon Children’s Medical Center)

Postdoctoral Position – Molecular Biology (Faculty of Informatics, Masaryk University)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.